This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Choosing a tricyclic antidepressant

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Tricyclic antidepressants may be divided into:

  • sedating
  • non-sedating

When there is a risk of the patient taking an overdose it is usually preferable to choose an SSRI, if a tricyclic is essential then lofepramine may be the safest drug.

Tricyclic antidepressants (with the exception of lofepramine) are more dangerous in overdose than other equally effective drugs recommended for routine use in primary care (1).

Tricyclic antidepressants (with the exception of lofepramine) should not be prescribed for patients with a:

  • high risk of serious cardiac arrhythmias
  • recent myocardial infarction

Dosulepin should not be initiated routinely because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose (1). NICE advise that dosulepin should not be prescribed (2).

Reference:

  1. NICE (April 2007). Management of depression in primary and secondary care
  2. NICE (October 2009). Depression updated guideline.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.